	US 12,436,149 B2
	Inflammatory bowel disease diagnosis method, diagnosis probe and diagnosis kit
Tsuyoshi Shirai, Miyagi (JP); Hiroshi Fujii, Miyagi (JP); Tomonori Ishii, Miyagi (JP); Hideo Harigae, Miyagi (JP); Yoichi Kakuta, Miyagi (JP); Atsushi Masamune, Miyagi (JP); and Tomoyuki Mutoh, Miyagi (JP)
Assigned to TOHOKU UNIVERSITY, Miyagi (JP)
Appl. No. 17/631,117
Filed by TOHOKU UNIVERSITY, Miyagi (JP)
PCT Filed Aug. 25, 2020, PCT No. PCT/JP2020/031986 § 371(c)(1), (2) Date Jan. 28, 2022, PCT Pub. No. WO2021/039771, PCT Pub. Date Mar. 4, 2021.
Claims priority of application No. 2019-156558 (JP), filed on Aug. 29, 2019.
Prior Publication US 2022/0276243 A1, Sep. 1, 2022
Int. Cl. G01N 33/53 (2006.01); G01N 33/564 (2006.01)

CPC G01N 33/564 (2013.01) [G01N 2800/065 (2013.01); G01N 2800/50 (2013.01); G01N 2800/52 (2013.01); G01N 2800/54 (2013.01)]

7 Claims

1. A method for determining a risk of recurrence of inflammatory bowel disease in a subject and treating said subject, comprising:

contacting a sample collected from a subject with an endothelial cell protein C receptor (EPCR);

measuring an amount of the anti-endothelial cell protein C receptor antibody (anti-EPCR antibody) in the sample collected from a subject;

comparing the measured value with a reference value; and

determining that the amount of the anti-EPCR antibody in the sample collected from the subject is higher than the reference value and treating the subject;

wherein the sample is blood, serum, or plasma, and the subject is a human, and

wherein the treatment is selected from the group consisting of surgery, exercise therapy, dietary therapy, administration of an anti-inflammatory drug, administration of an immunosuppressive drug, or administration of an anti-TNF-α-antibody.